Business Wire
02 Oct 2026, 06:30 UTC · 12h ago
Verdict
Headline takes no side. We score 2185 +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Italfarmaco and JCR Pharmaceuticals have entered into an exclusive license agreement for the development and potential commercialization of JR-141 for Hunter Syndrome in the US, Europe, and Latin America.
Newannouncement dated 2026-10-02
More positive than 79% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of ticker scores this week
JCR entered into an exclusive license agreement to develop and commercialize JR-141.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
7h ago
—
No price for 2185 right now — the quote feed didn't answer.
2185 chart →
